This Focus Session is a fast-paced, bottom-line-heavy, annual review of the highest impact peer-reviewed publications and newsmaker events across the field of Addiction Medicine, from 2024 through early 2025. Two presenters alternate covering a Top Ten, and select themes and publications particularly likely to change clinical practice.
Learning Objectives:
Learners will be able to:
Rank and list the most read and highest impact addiction medicine publications from 2024-2025
Integrate the most recent peer-reviewed findings into existing standards and clinical practice guidelines
Consider the impact on media coverage and public attention on article rankings and overall impact
Disclosure(s):
Sarah E. Wakeman, MD, FASAM: No financial relationships to disclose
JOSHUA D. LEE, MD, MSc: Alkermes: in-kind study drug (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Indivior: in-kind study drug (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Oar Health: Consultant/Advisory Board (Ongoing), Stockholder/Ownership Interest (excluding diversified mutual funds) (Ongoing)
